



FOR PATIENTS, SURVIVORS & HEALTHCARE PROFESSIONALS / **CE CREDITS AVAILABLE**

2023 RHODE ISLAND CANCER SUMMIT

A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023: NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

October 11, 2023





Presenting Sponsor

Yale NewHaven **Health**

Smilow Cancer Hospital

Gold Sponsor













Silver Sponsor









































A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023

NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

AGENDA

8:00 am - 8:15 am Welcoming Remarks

James Willsey, Conference Facilitator

Patricia Stout, DNP, APRN-CNP, Board Chair, PRCRI; Associate Clinical Professor,

College of Nursing, University of Rhode Island **Megan Daniel**, Executive Director, PRCRI

8:15 am - 8:20 am Greetings from the Rhode Island Department of Health

Kristine Campagna, MEd, Associate Director of Health, Division of Community,

Health and Equity, Rhode Island Department of Health

8:20 am - 8:50 am A Research Agenda to Address Cancer-Related Financial Hardship

Janet de Moor, PhD, MPH, Deputy Associate Director of the Healthcare Delivery

Research Program, National Cancer Institute

8:50 am - 9:50 am Keynote: High Cost of Cancer Drugs: Causes and Solutions

S. Vincent Rajkumar, MD, Professor of Medicine, Division of Hematology,

Department of Internal Medicine and Division of Hematopathology, Department of

Laboratory Medicine and Pathology, Mayo Clinic

9:50 am - 10:00 am Award Presentations

10:00 am - 10:25 am Exhibitor Break

10:25 am - 11:25 am Roles of the Oncology Team to Address Cancer Related Financial Toxicity (CRFT)

Moderated by: James Willsey

Heather Coelho, BSN, RN, OCN, CN-BN, Breast Health Nurse Navigator, Program in

Women's Oncology, Women & Infants Hospital

Max McMahon, LICSW, Social Worker, Lank Center for Genitourinary Oncology,

Dana-Farber Cancer Institute

11:25 am – 11:55 am Sponsor Break, Snacks

11:55 am – 12:55 pm Opportunities for Action: Reducing Financial Toxicity for Cancer Patients

Moderated by: Robert Legare, MD, FACP, Associate Professor of Clinical Medicine,

Yale School of Medicine; Medical Director, Smilow Cancer Hospital Care Center at

Westerly, RI and Waterford, CT

Cori Chandler, MPA, Senior State & Local Campaigns Manager, American Cancer

Society Cancer Action Network

S. Vincent Rajkumar, MD

Janet de Moor, PhD, MPH

12:55 pm – 1:00 pm Closing Remarks



A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023

NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

OUR PRESENTERS



Dr. Janet de Moor is the Acting Associate Director of the Healthcare Delivery Research Program in the Division of Cancer Control and Population Sciences at the National Cancer Institute. In this role, she leads research and programmatic activities focused on cancer-related financial hardship, employment outcomes after cancer, and cancer survivorship. Dr. de Moor previously served as a Program Director in the Healthcare Delivery Research Program and prior to that the Office of Cancer Survivorship. Before coming to the National Cancer Institute in 2011, Dr. de Moor was on the faculty of The Ohio State University College of Public Health. She received her Master of Public Health degree and Doctorate in Behavioral Science from the University of Texas Health Science Center at Houston School of Public Health.



S. Vincent Rajkumar, M.D., is the Edward W. and Betty Knight Scripps Professor of Medicine and is a Mayo Clinic Clinician Investigator. He is co-chair of the International Myeloma Working Group (IMWG), and Chair of the Eastern Cooperative Oncology Group (ECOG) myeloma committee. He serves as the Editor in Chief of Blood Cancer Journal, and Associate Editor for: Mayo Clinic Proceedings, Leukemia, and European Journal of Hematology. Dr. Rajkumar serves on the board of directors for the International Myeloma Foundation and is a member of the National Institutes of Health's Multiple Myeloma Steering Committee. Dr. Rajkumar is recognized internationally as a leading authority in the field of plasma cell disorders. His scientific

contributions include clinical trials, epidemiological studies, and laboratory research focused on myeloma and related disorders. He has led multiple clinical trials that have changed the treatment for the disease. He led the pivotal trial that led to the approval of thalidomide for the treatment of multiple myeloma in the United States. In 2014, based on his findings, he led an international effort that revised the diagnostic criteria for multiple myeloma and related plasma cell disorders.



Heather Coelho, RN, BSN, OCN, CN-BN, has been an oncology nurse at Women & Infant's Hospital for 22 years, from in-patient care to infusion therapy and for the last 13 years as a Certified Nurse Navigator in breast oncology. Heather was awarded Nurse of the Year by the Rhode Island and Southeastern Massachusetts Oncology Nursing Society. She is passionate about caring for all cancer patients. Heather has a magic wand in her office, and she is not afraid to use it!



2023 RHODE ISLAND CANCER SUMMIT A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023 NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

OUR PRESENTERS



Max McMahon, LICSW, is a clinical social worker at Dana Farber Cancer Institute in Boston where he works closely with an oncology team to address complex psychosocial issues that impact patients and families confronting serious illness. Max is also a (former) patient at Dana Farber, having been treated for Follicular lymphoma. Max worked as a hospice social worker during the pandemic and has also worked in educational, non-profit and public-sector industries. Max is a native Bostonian who has fond memories of lazy summer nights watching the PawSox at McCoy.



Robert Legare, MD, received his medical degree from Tufts University School of Medicine, and completed his residency training in Internal Medicine at Yale New Haven Hospital. He served as Co-Director of the Breast Health Center and Director of the Cancer Genetics and Prevention Program at the Women and Infants Hospital in Providence, RI. Dr. Legare is actively involved in clinical research focusing on breast and ovarian cancer as well as studying hereditary cancer syndromes. Robert is now currently Associate Professor of Clinical Medicine, Yale University School of Medicine; Medical Director, Smilow Cancer Hospital Care Center at Westerly, RI and Waterford, CT.



Cori Chandler is a Sr. State & Local Campaigns Manager for the American Cancer Society Cancer Action Network (ACS CAN). She attended Rhode Island College, earning a B.A. in political science and public administration with a minor in psychology. In 2019, she completed a policy fellowship at the University of Rhode Island while pursuing her Master of Public Administration. Prior to this role, she served as the Rhode Island Government Relations Director for ACS CAN. When not advocating for cancer patients, she enjoys spending time with her adorable son and husband.



A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023

NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

AWARDS

The Partnership is recognizing two individuals whose contributions have helped to prevent cancer and improve access to quality cancer care for all Rhode Islanders.

Senate Champion Partnership Award

The 2023 recipient is the late **Senator Maryellen Goodwin**

The Senate Champion Partnership Award recognizes a Rhode Island Senator who champions and sponsors legislation that increases access to life-saving screening tests, help advance research for novel treatment therapies, and improves outcomes for cancer patients, survivors, and families.

The Partnership Public Health Award

The 2023 recipient is Linda M. Dziobek, RN

The Partnership Public Health Award recognizes an individual for their commitment to and outstanding achievements in health equity, public health, and reducing the burden of cancer in Rhode Island. This award is for a champion of the cancer community, someone who listens, confronts barriers, and truly makes a difference in the lives of those with cancer, their families, and friends.

PLANNING COMMITTEE

Linda Dziobek

Thank you to our Summit Planning Committee, Volunteers and Consultants!

For your dedicated efforts in making this year's Cancer Summit a success.

Lynn Basilio Todd Ellison **Diane Martins** Matthew Blanchette Deb Erickson-Owens **Arthur Plitt** Jayme Dandeneau Dalton Everett Mike Ratté C Kelly Smith Lora Fox Megan Daniel Sheri Daniel Patricia Stout Maria Gemma Regina Donald Norma Hardy Jim Willsey Joseph Dziobek Nancy Lebrun Susan Yarbrough

Lou Leta



A DECADE OF PROMISE FOR **SURVIVORSHIP IN 2023**

NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

CONTINUING EDUCATION

CEUs For Today's Summit



INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and Partnership to Reduce Cancer in Rhode Island. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **live** activity for a maximum of **3.5** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **3.5** nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this knowledge-based event for pharmacists to receive 0.35 CEUs in pharmacy education. The Universal Activity Number is JA4008229-9999-23-095-L04-P.

After credit is claimed, an unofficial statement of credit is immediately available on Training and Continuing Education Online (TCEO). Official credit will be uploaded within 60 days on the NABP/CPE Monitor

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.4 CEUs for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 3.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are **3.5**. CDC provider number **98614**.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer **4.0** CPH recertification credits for this program.



As a Jointly Accredited Organization, CME Outfitters, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) ASWB approved continuing education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final

authority on courses accepted for continuing education credit. Social workers completing this course receive 3.5 general continuing education credits.



3.5 CE hours are pending by the NCRA Program Recognition Committee. Please follow up with Nancy Lebrun (NancyL@HARI.org) for the certificate of attendance.



A DECADE OF PROMISE FOR SURVIVORSHIP IN 2023

NAVIGATING FINANCIAL TOXICITIES OF CANCER TREATMENT AND BEYOND

THE PARTNERSHIP

Mission Statement

"The mission of the Partnership to Reduce Cancer in Rhode Island (the Partnership) is to prevent cancer and improve the quality of life of all Rhode Islanders living with cancer through education, advocacy, and supportive resources."

Vision Statement

"Create a cancer free Rhode Island through leadership and community engagement."

Guiding Values

- Inclusive and equitable healthcare.
- The efforts of all who work with and on behalf of the Partnership in pursuit of its mission.
- A culture of integrity, collaboration, transparency, and excellence.
- The voices, experiences, and personal stories of cancer survivors and their families.
- A diverse, engaged membership and their role in and contributions to the organization.
- Innovation through evidence-based practice, quality improvement, and research.

Special Thanks to Amica for printing our Summit materials. Your continuous support and is greatly appreciated.

The Partnership has grown significantly over the past year thanks to the support of our funders, partners, and members.

We have four work groups currently meeting to address palliative care, oral health, lung cancer screening, and prevention, screening and early detection. We launched <u>screenri.org</u>, a statewide resource on lung cancer screening and eligibility. We continued our work to provide outreach to at-risk individuals for breast and cervical cancer and enroll eligible women into the Women's Cancer Screening Program. We also held our inaugural Spring into Summer fundraiser, which received an outpouring of support from our local communities.

The Partnership would like to thank all members and organizations who have contributed to our work thus far, and we look forward to continuing to build relationships and start new ones.

Ready to join us?

Please fill out our membership form online by scanning the QR code or contact us at reducecancer@gmail.com with any questions regarding the membership application.



For more information or to access our resources, please visit us at www.PRCRI.org!



www.PRCRI.org



Reducecancer@gmail.com







